Dexfenfluramine
4635792
215570619
2008-05-28T20:00:58Z
ChemNerd
2246483
Removed category "Phenethylamines"; Quick-adding category "Amphetamines" (using [[WP:HOTCAT|HotCat]])
{{drugbox
| IUPAC_name = ''N''-Ethyl-1-[3-(trifluoromethyl)phenyl]-propan-2-amine
| image = Dexfenfluramine.png
| CAS_number = 3239-44-9
| ATC_prefix = A08
| ATC_suffix = AA04
| ATC_supplemental =
| PubChem = 3337
| DrugBank = APRD00648
| C=12 | H=16 | F=3 | N=1
| molecular_weight = 231.257 g/mol
| bioavailability =
| protein_bound = 36%
| metabolism =
| elimination_half-life = 17-20 hours
| pregnancy_category =
| legal_US = Schedule IV
| legal_status = Withdrawn from market
| routes_of_administration =
}}
<!-- Deleted image removed: [[Image:ReduxAd.png|thumb|300px|left|A direct-to-physician advertisement for Redux.]] -->
'''Dexfenfluramine''', also marketed under the name '''Redux''', is a serotoninergic [[anorectic]] drug. It was for some years in the mid-1990s approved by the United States [[Food and Drug Administration]] for the purposes of [[weight loss]]. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by [[sibutramine]], which is a safer alternative to both dexfenfluramine and [[fenfluramine]].
The drug was manufactured by [[Interneuron Pharmaceuticals]] and marketed by [[Wyeth-Ayerst Laboratories]]. It is the [[enantiomer]] of [[levofenfluramine]].
==See also==
*[[Fen-phen]]
==References==
*[http://www.fda.gov/cder/news/phen/fenphenpr81597.htm ''FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)'']
[[Category:Withdrawn drugs]]
[[Category:Serotonin receptor agonists]]
[[Category:Amphetamines]]
{{pharma-stub}}
{{Antiobesity preparations}}
[[de:Dexfenfluramin]]